Maternal and Perinatal Outcomes in Women with Insulin Resistance

 

 Buy Article Permissions and Reprints

Abstract

Objective This study aims to estimate the risks of adverse maternal and perinatal outcomes in women with insulin resistance below the threshold of gestational diabetes mellitus (GDM).

Methods This was a retrospective cohort study of 5,983 women with singleton pregnancies undergoing universal GDM screening between 24 and 28 weeks gestation. Subjects were divided into those with a normal 1-hour glucose challenge test (GCT), those with an elevated GCT with all normal values on a 3-hour glucose tolerance test (GTT), and those with an elevated GCT with one abnormal value on GTT. Outcomes included macrosomia, pregnancy-induced hypertension (PIH), cesarean section and operative delivery, shoulder dystocia, indicated-preterm birth, and other neonatal outcomes. Logistic regression was performed to compare outcomes among groups.

Results The risk of macrosomia was increased for those with an elevated GCT and all normal values on GTT (adjusted odds ratio [aOR], 1.71; 95% confidence interval [CI]: 1.12, 1.97), and for those with an elevated GCT and one abnormal value (aOR, 2.69; 95% CI: 1.49, 4.83). Risks of PIH, cesarean section, and indicated-preterm birth were also increased in those with an elevated 1-hour GCT and no GDM.

Conclusion There are increased risks of macrosomia, PIH, indicated-preterm birth, and cesarean section among those with insulin resistance even in the absence of GDM.

Note

Dr. Cahill was a Robert Wood Johnson Foundation Faculty Physician Scholar which partially supported this work. Dr. Temming is supported by a NIH T32 training grant (5T32HD055172–05). This publication was also supported by the NIH National Center for Advancing Translational Sciences (NCATS), components of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research (grant number UL1 TR000448). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCATS or NIH.

• References

• 1 Committee on Practice Bulletins--Obstetrics. Practice bulletin no. 137: Gestational diabetes mellitus. Obstet Gynecol 2013; 122 (2 Pt 1): 406-416
  CrossrefPubMedGoogle Scholar
• 2 Metzger BE, Lowe LP, Dyer AR , et al; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008; 358 (19) 1991-2002
  CrossrefPubMedGoogle Scholar
• 3 Dodd JM, Crowther CA, Antoniou G, Baghurst P, Robinson JS. Screening for gestational diabetes: the effect of varying blood glucose definitions in the prediction of adverse maternal and infant health outcomes. Aust N Z J Obstet Gynaecol 2007; 47 (4) 307-312
  CrossrefPubMedGoogle Scholar
• 4 Landon MB, Spong CY, Thom E , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009; 361 (14) 1339-1348
  CrossrefPubMedGoogle Scholar
• 5 Landon MB, Mele L, Spong CY , et al; Eunice Kennedy Shriver National Institute of Child Health, and Human Development (NICHD) Maternal–Fetal Medicine Units (MFMU) Network. The relationship between maternal glycemia and perinatal outcome. Obstet Gynecol 2011; 117 (2 Pt 1): 218-224
  CrossrefPubMedGoogle Scholar
• 6 ACOG Committee on Practice Bulletins--Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002; 99 (1) 159-167
  CrossrefPubMedGoogle Scholar